Next Article in Journal
Pseudomonas aeruginosa: Recent Advances in Vaccine Development
Next Article in Special Issue
Myocarditis or Pericarditis Following the COVID-19 Vaccination in Adolescents: A Systematic Review
Previous Article in Journal
First COVID-19 Booster Dose in the General Population: A Systematic Review and Meta-Analysis of Willingness and Its Predictors
Previous Article in Special Issue
Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 7
10.3390/vaccines10071096
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report

by
Marco Infante
1,2,3,4,*,
Andrea Fabbri
5,
Nathalia Padilla
6,
Francesca Pacifici
5,
Pasquale Di Perna
1,
Laura Vitiello
7,
Alessandra Feraco
8,9,
Maria Giuliano
1,
Marina Passeri
1,
Massimiliano Caprio
8,9,
Camillo Ricordi
2,
David Della-Morte
5,9,10,† and
Luigi Uccioli
1,†
1
CTO Andrea Alesini Hospital, Division of Endocrinology and Diabetes, Department of Systems Medicine, University of Rome Tor Vergata, Via San Nemesio 21, 00145 Rome, Italy
2
Cell Transplant Center, Diabetes Research Institute (DRI), University of Miami Miller School of Medicine, 1450 NW 10th Ave, Miami, FL 33136, USA
3
Section of Diabetology, UniCamillus, Saint Camillus International University of Health Sciences, Via di Sant’Alessandro 8, 00131 Rome, Italy
4
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Via Cola di Rienzo 28, 00192 Rome, Italy
5
Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
6
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Colonia Centroamérica L-823, Managua 14048, Nicaragua
7
Laboratory of Flow Cytometry, IRCCS San Raffaele, Via di Val Cannuta 247, 00166 Rome, Italy
8
Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele, Via di Val Cannuta 247, 00166 Rome, Italy
9
Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, Via di Val Cannuta 247, 00166 Rome, Italy
10
Department of Neurology, Evelyn F. McKnight Brain Institute, University of Miami Miller School of Medicine, 1120 NW 14th St, Miami, FL 33136, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Vaccines 2022, 10(7), 1096; https://doi.org/10.3390/vaccines10071096
Submission received: 30 May 2022 / Revised: 21 June 2022 / Accepted: 4 July 2022 / Published: 8 July 2022
(This article belongs to the Special Issue Vaccine Safety)
Browse Figures
Versions Notes

Abstract

Type 1 diabetes (T1D), which is caused by the autoimmune destruction of insulin-secreting pancreatic beta cells, represents a high-risk category requiring COVID-19 vaccine prioritization. Although COVID-19 vaccination can lead to transient hyperglycemia (vaccination-induced hyperglycemia; ViHG), its influence on the course of the clinical remission phase of T1D (a.k.a. “honeymoon phase”) is currently unknown. Recently, there has been an increasing concern that COVID-19 vaccination may trigger autoimmune phenomena. We describe the case of a 24-year-old young Italian man with T1D who received two doses of the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine during a prolonged honeymoon phase. He experienced a transient impairment in glucose control (as evidenced by continuous glucose monitoring) that was not associated with substantial changes in stimulated C-peptide levels and islet autoantibody titers. Nonetheless, large prospective studies are needed to confirm the safety and the immunometabolic impact of the BNT162b2 vaccine in T1D patients during the honeymoon phase. Thus far, T1D patients who are going to receive COVID-19 vaccination should be warned about the possible occurrence of transient ViHG and should undergo strict postvaccination surveillance.
Keywords: T1D; honeymoon phase; clinical remission; autoimmunity; hyperglycemia; beta cell; C-peptide; COVID-19 vaccine; SARS-CoV-2 BNT162b2 mRNA vaccine; COVID-19 vaccination-induced hyperglycemia T1D; honeymoon phase; clinical remission; autoimmunity; hyperglycemia; beta cell; C-peptide; COVID-19 vaccine; SARS-CoV-2 BNT162b2 mRNA vaccine; COVID-19 vaccination-induced hyperglycemia

Share and Cite

MDPI and ACS Style

Infante, M.; Fabbri, A.; Padilla, N.; Pacifici, F.; Di Perna, P.; Vitiello, L.; Feraco, A.; Giuliano, M.; Passeri, M.; Caprio, M.; et al. BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report. Vaccines 2022, 10, 1096. https://doi.org/10.3390/vaccines10071096

AMA Style

Infante M, Fabbri A, Padilla N, Pacifici F, Di Perna P, Vitiello L, Feraco A, Giuliano M, Passeri M, Caprio M, et al. BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report. Vaccines. 2022; 10(7):1096. https://doi.org/10.3390/vaccines10071096

Chicago/Turabian Style

Infante, Marco, Andrea Fabbri, Nathalia Padilla, Francesca Pacifici, Pasquale Di Perna, Laura Vitiello, Alessandra Feraco, Maria Giuliano, Marina Passeri, Massimiliano Caprio, and et al. 2022. "BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report" Vaccines 10, no. 7: 1096. https://doi.org/10.3390/vaccines10071096

APA Style

Infante, M., Fabbri, A., Padilla, N., Pacifici, F., Di Perna, P., Vitiello, L., Feraco, A., Giuliano, M., Passeri, M., Caprio, M., Ricordi, C., Della-Morte, D., & Uccioli, L. (2022). BNT162b2 mRNA COVID-19 Vaccine Does Not Impact the Honeymoon Phase in Type 1 Diabetes: A Case Report. Vaccines, 10(7), 1096. https://doi.org/10.3390/vaccines10071096

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop